The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GNMSF | +60.63% | -26.13% | -5.88% | +1,755% |
| S&P | +14.39% | +76.41% | +12.02% | +512% |
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.
No news articles found for Genmab A/s.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.02B | 25.3% |
| Gross Profit | $964.00M | 24.3% |
| Gross Margin | 94.32% | -0.7% |
| Market Cap | $18.96B | 27.2% |
| Market Cap / Employee | $7.07M | 25.0% |
| Employees | 2.7K | 1.7% |
| Net Income | $401.00M | 115.1% |
| EBITDA | $478.09M | 45.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.76B | 85.5% |
| Accounts Receivable | $1.05B | 10.7% |
| Inventory | 14 | 31.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $126.00M | -6.1% |
| Short Term Debt | $16.00M | 17.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 22.87% | 10.5% |
| Return On Invested Capital | 18.19% | 1.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $561.13M | 85.5% |
| Operating Free Cash Flow | $563.40M | 82.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 11.71 | 10.89 | 10.28 | 12.80 | -44.81% |
| Price to Book | 2.76 | 2.37 | 2.53 | 3.57 | 6.78% |
| Price to Sales | 4.25 | 3.84 | 3.77 | 5.26 | -2.57% |
| Price to Tangible Book Value | 4.88 | 3.98 | 4.21 | 5.93 | -5.94% |
| Price to Free Cash Flow TTM | 12.22 | 10.85 | 12.79 | 15.02 | -7.66% |
| Enterprise Value to EBITDA | 31.86 | 45.69 | 26.44 | 32.56 | -17.94% |
| Free Cash Flow Yield | 8.2% | 9.2% | 7.8% | 6.7% | 8.29% |
| Return on Equity | 23.2% | 22.7% | 26.0% | 28.1% | 91.80% |
| Total Debt | $142.88M | $143.00M | $148.00M | $142.00M | -3.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
